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Screening for Chlamydia trachomatis
Opportunistic approaches have little evidence to support them
Sexual infections and teenage pregnancies disproportion-
ately affect people living in poverty and social exclu-
sion. In 2004, the government white paper “Choosing 
health”1 identified sexual health as a priority area for 
improvement and service development. The paper 
followed the publication of the National Strategy for 
Sexual Health and HIV,2 which aims to provide “better 
prevention, better services, and better sexual health.” 
The strategy described the implementation of a broad 
National Chlamydia Screening Programme (NCSP) in 
accordance with the National Health Service plan, which 
included “a commitment to improving the prevention 
of ill health and providing screening programmes where 
they are appropriate.” 
In this week’s BMJ, an analysis by Low shows how 
acceptance of the effectiveness of chlamydial screen-
ing programmes in Sweden and the United States 
supported the funding of the National Chlamydia 
Screening Programme before the balance of benefits 
and harms was thoroughly understood.3
Chlamydia is the most common sexually transmitted 
disease in England. Its prevalence has increased stead-
ily since the mid-1990s, and rose by 300% from 1995 to 
2004. The main burden of infection affects women aged 
16-19 and men aged 20-24 years. Although often asymp-
tomatic, associated problems such as pelvic inflammatory 
disease, infertility, ectopic pregnancy, epididymo-orchitis, 
ophthalmic complications, and neonatal complications 
are well described. As with most sexually transmitted 
infections, Chlamydia trachomatis may be a cofactor for 
HIV transmission.
Chlamydia is the only sexually transmitted infection 
for which population screening has been implemented. 
Ideally, a screening programme for infectious disease 
should identify and treat a sufficient number of infec-
tions to reduce transmission in the community, and thus 
reduce prevalence. There are two main approaches to 
the design of screening programmes—proactive and 
opportunistic. Proactive screening—for example, cervical 
screening in the United Kingdom—uses the population 
register to identify the target population. People are con-
tacted at intervals defined by the transmission dynamics 
(which use epidemiological data to estimate the spread 
or transmission of infection in the absence of interven-
tion within a defined time frame), uptake of screening 
is monitored, and non-attenders are contacted. Oppor-
tunistic screening targets people who attend a healthcare 
setting. Thus, it reaches only those who attend the serv-
ice and regular rescreening is unlikely to occur. It also 
relies upon the health provider remembering to give 
information and offer the test to those deemed eligible.
The National Chlamydia Screening Programme 
in England began in 2001.4 It uses an opportunistic 
approach and targets sexually active people under 25 
years of age within a variety of healthcare settings. It is a 
dynamic model, which evolves as evidence accumulates. 
In the third year of the programme, 1777 venues were 
involved in 26 programme areas, and nearly 100 000 
people were screened. Most of these people were women 
(82%). The incidence of chlamydia infection was 10.1% 
(95% confidence interval 10.0 to 10.3). Of 8816 posi-
tive cases, around 10 000 partners were reported; 49% 
of partners were tested and 33% were treated. This may 
seem like a low proportion, but contact tracing is notori-
ously difficult. In a prior attempt to develop national 
standards for measuring outcomes of care for gonor-
rhoea and chlamydia in genitourinary medicine clinics, 
reports detailing chlamydia outcomes were identified. 
In large city clinics, 0.43 (0.30 to 0.62) contacts per case 
were screened compared with 0.64 (0.58 to 0.70) contacts 
per case in other clinics.
The analysis by Low3 cites a lack of evidence from 
randomised controlled trials to support the opportun-
istic screening method. The opportunistic approach is 
used in most chlamydia screening programmes in the 
US, Sweden, and England. Studies showing a reduction 
in the rates of chlamydia, pelvic inflammatory disease, 
and ectopic pregnancy over time have been widely cited 
in support of such screening.5 6 A concurrent decrease 
in the diagnosis of gonorrhoea in Sweden and the UK 
has occurred, but has been ascribed to extensive safe 
sex campaigns rather than the chlamydia screening pro-
gramme. However, rates of chlamydia in Sweden, the 
rest of Europe, and the US have been steadily increasing 
since the mid-1990s despite the implementation of oppor-
tunistic screening. This increase in rates may reflect the 
outcomes of targeting more people, the use of more sensi-
tive technology, or a genuine increase in prevalence. 
Critics of the National Chlamydia Screening Pro-
gramme have focused on several issues. These include 
the use of an opportunistic screening method and its 
associated fragility; the reduced participation of general 
practitioners in the programme compared with the pilot 
schemes, in which doctors were paid for each patient 
enrolled and participation was mandatory; the low 
number of men screened; contact tracing failing to reach 
all partners; and cost effectiveness. In two pilot sites, all 
general practitioners took part, were paid for each patient 
enrolled,5 and generated the highest proportion of tests 
and cases, achieving an effective screening rate of 50%.3 
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Coeliac disease in primary care
Is common, underdiagnosed, and can present with non-specific symptoms
Coeliac disease affects around 1% of the general popula-
tion, but most cases are unrecognised and diagnosis is 
often delayed considerably.1 2 This is surprising, given 
how common the disease is and how serious its effects 
can be.1 3 4 Several possible reasons exist for this delay; 
the most important is that most patients with coeliac dis-
ease do not have typical symptoms of malabsorption. 
Even if these symptoms are present their non-specific 
nature may not trigger diagnostic suspicion of coeliac 
disease. Other atypical presentations can occur, espe-
cially in older patients,5 and the disease may even be 
seen in obese people.6
In this week’s BMJ, Hopper and colleagues report a 
validated clinical prediction rule to determine an effec-
tive diagnostic method of detecting all cases of coeliac 
disease in people referred for gastroscopy. People with 
positive tissue transglutaminase antibodies and “low risk 
symptoms,” as well as those with the high risk symptoms 
of diarrhoea, weight loss, and anaemia, were investi-
gated with duodenal biopsy, while those with a negative 
antibody result and low risk symptoms were not biop-
sied.7 They found that pre-endoscopy serological testing 
combined with biopsy of people with high risk symp-
toms had a sensitivity of 100%. They also found that a 
proportion of high risk patients with positive serology 
turn out not to have coeliac disease on biopsy, which 
should prompt reconsideration of the need for a life-
long gluten-free diet. An accompanying commentary in 
this issue by Graber and Kumar discusses the potential 
application of the decision rule to clinical practice.8
Coeliac disease is characterised by a lifelong intoler-
ance to certain storage proteins contained in wheat, rye, 
and barley, collectively known as gluten, and it is an 
unusual combination of food intolerance and autoimmu-
nity. Chronic inflammation of proximal small intestinal 
mucosa, with atrophy of small intestinal villi, is associ-
ated with impaired absorption of nutrients and increased 
secretion of water and solids because of abnormal intes-
tinal permeability. The disease has been classified into 
four phenotypes.2 In classic coeliac disease, patients have 
intestinal malabsorption and gastrointestinal symptoms, 
whereas the atypical (most common) form of the disease 
has few or no gastrointestinal symptoms. Atypical disease 
has other problems, however, including iron deficiency 
anaemia, osteoporosis, short stature, infertility, and 
unfavourable outcomes of pregnancy.9 In silent coeliac 
disease, asymptomatic patients are found to have gluten 
induced villous atrophy, and in latent disease, patients 
may have normal mucosa or may show villous atrophy, 
which improves after gluten withdrawal.
The gold standard for the diagnosis of coeliac disease 
is a proximal small intestinal (duodenal) biopsy, but 
serum testing for antigliadin and endomysial antibod-
ies is also available and offers reasonable sensitivity and 
specificity. The American Gastroenterology Association 
recommends the use, in primary care, of the IgA tissue 
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In the programme itself, participation of general practi-
tioners is optional and largely unremunerated. In 2005-6, 
the effective screening rate was less than 5% in more 
than half of programme areas. However, the National 
Chlamydia Screening Programme is in its third phase 
of conception and is still expanding, with a large scale 
implementation due later this year. It has responded with 
innovative strategies, such as pharmacy based screening 
programmes, to reach target groups.
A proactive approach to chlamydia screening might be 
difficult and unacceptable to some people, as screening 
would start at 16 years of age and not all of those invited 
would be sexually active. As the aim of the programme 
is to reduce the prevalence of chlamydia, infected men 
would need to be identified, and this might have a signifi-
cant impact on its cost effectiveness. Strategies from the 
men’s health forum study (supported by the Department 
of Health), such as depositing test kits and health pro-
motion literature in the workplace, may prove useful.7 
Cost is being questioned by Low3 in light of conflicting 
opinions regarding the prevalence of morbidity related 
to chlamydia, and mathematical modelling relies on high 
levels of acceptance, uptake, and coverage of screening, 
in addition to annual repeat testing and partner notifica-
tion—areas that are continually being developed in the 
National Chlamydia Screening Programme.
The Department of Health has recruited the National 
Institute for Health and Clinical Excellence (NICE) 
to produce public health guidance on interventions, 
including screening, designed to reduce the transmis-
sion of chlamydial infection, together with other sexually 
transmitted infections and pregnancy in the under 18s.8 
Recommendations include identifying people at risk of 
infection and providing sexual health counselling. One 
to one interventions, as well as group and peer based 
approaches, are highlighted throughout the document. 
It discusses partner notification and treatment; evidence 
based methods that have yielded higher contact rates 
than conventional contact tracing, such as mailing home 
sampling urine kits and patient delivered partner therapy 
(this strategy is not legal in the UK). Primary care trust 
commissioners are asked to ensure that sexual health 
services are in place to meet local needs.
Sexual health has emerged as a government priority. 
Despite multiple campaigns in the media, the diagnosis 
of sexually transmitted infections continues to increase. 
Most people who are affected are unlikely to seek sexual 
health testing and may only be assessed via a proactive 
approach rather than the opportunistic screening pro-
gramme currently offered.
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The 2006 WHO child growth standards
Have implications for nutrition programmes in emergencies
In April 2006, the World Health Organization released 
its new WHO child growth standards,1 16 years after a 
WHO working group on infant growth recommended 
that these standards should describe how children 
should grow rather than how they actually grow.2 The 
basis for the new growth standards was six popula-
tion based studies of infants and children from Ghana, 
India, Norway, Brazil, Oman, and North America, 
undertaken between 1997 and 2003. Participants were 
fed according to accepted international nutritional 
standards (including breast feeding), and their mothers 
were adequately nourished and avoided known adverse 
factors such as tobacco exposure.
The new growth standards show that children born 
in different regions of the world can and should grow 
equally well, and they also show that sex and ethnic 
origin are minor determinants of growth compared 
with adequate nutrition, environment, and health.2 
However, as expected, important differences in the 
diagnosis of malnutrition emerge when the standard 
cut-offs are applied using either the National Center for 
Health Statistics (NCHS)-WHO reference or the WHO 
2006 growth standards.
In this week’s BMJ, Seal and Kerac report the impli-
cations of adopting the new WHO child growth stand-
ards in emergency and non-emergency child feeding 
programmes using secondary data analysis from three 
nutritional surveys in emergency settings.3 Nutritional 
status can be expressed using either z scores or per-
centage of the median values. WHO recommends 
that weight for height should be expressed as a z score. 
However, while not recommended by WHO, many 
agencies working in emergency settings use weight for 
height expressed as a percentage of the median as the 
criterion for admission to feeding programmes.
Seal and Kerac tabulated and compared the weight 
for height z score and percentage of the median cut-offs 
for moderate and severe acute malnutrition from both 
the NCHS-WHO growth reference and the new WHO 
standards. With the new WHO standards, a marked 
increase (0.5-2.7) in the prevalence of severe wasting 
was seen if weight for height was expressed as a z score 
(weight for height ≤3 z scores), confirming a previous 
report that showed an increase of 1.5-2.5.4 Paradoxi-
cally, however, the new WHO standards showed a 
significantly lower prevalence of severe wasting when 
expressed as a percentage of the median (weight for 
height <70% of the median). These findings have seri-
ous programmatic and resource implications.
In emergencies, growth standards are used for 
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transglutaminase antibody test as the single diagnostic 
serological test.2 However, coeliac disease may cause 
IgA deficiency, so that IgG endomysial antibodies and 
transglutaminase antibodies should be checked if biopsy 
is positive but the IgA tests are negative. Furthermore, 
because the histology of the disease can be patchy, care-
ful quadrantic biopsies from the duodenum are needed. 
Even then difficulties in the preparation and interpre-
tation of histological material may create diagnostic 
uncertainty, so that follow-up and reinvestigation may 
be needed to confirm the diagnosis.10
Coeliac disease is more common in people whose 
first degree relatives have the condition and in patients 
with iron deficiency anaemia, low bone mineral den-
sity, and other autoimmune disorders, such as type 1 
diabetes mellitus and autoimmune thyroid and liver dis-
ease. Associations between coeliac disease and several 
other conditions including Down’s syndrome, Turner’s 
syndrome, and schizophrenia have been reported. The 
possible excess of coeliac disease in patients with irritable 
bowel syndrome and the need to test for the condition in 
the routine investigation of intermittent abdominal pain 
and bloating remain controversial. In a recent treatment 
trial of irritable bowel syndrome in the United King-
dom the prevalence of coeliac disease was 0.7%, similar 
to the population mean.11 Coeliac disease is associated 
with excess mortality, including an increased risk of non-
Hodgkin’s lymphoma and other cancers.12
A gluten-free diet not only protects against non-
Hodgkin’s lymphoma, corrects anaemia, and restores 
normal nutritional and biochemical status, but it also 
substantially improves quality of life, particularly if 
troublesome gastrointestinal symptoms have been 
present.13
What then are the important messages for primary 
care? Firstly, patients with unexplained diarrhoea, anae-
mia, weight loss, infertility, recurrent miscarriage and 
low birthweight babies, or low bone mineral density 
are at increased risk of coeliac disease and should be 
investigated in primary care with antibody tests. Sec-
ondly, risk of coeliac disease is higher in patients with 
a first degree relative with the condition and in those 
with other autoimmune disorders such as type 1 dia-
betes (with which coeliac disease sometimes shares the 
HLA markers DQ2 and DQ8) and autoimmune thy-
roid and liver disease, and serum antibody testing should 
be considered. Patients with gastrointestinal symptoms 
strongly suggestive of coeliac disease who test negative 
should be referred for a specialist opinion. In all patients 
with positive antibodies the diagnosis of coeliac disease 
must be confirmed by endoscopic biopsy, for which 
specialist referral will also usually be required. Thirdly, 
while a lifelong gluten-free diet can reverse the effects of 
gluten enteropathy, the diagnosis, once again, must be 
confirmed by a small intestinal biopsy. Hopper and col-
leagues’ study offers an attractive algorithmic approach 
to identifying coeliac disease, and evaluation of this algo-
rithm in a primary care setting is now required. 
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The World Health Organization’s study on domestic vio-
lence against women highlights the need for immediate 
action. The study across 10 countries used robust cultu- 
rally appropriate methods to assess the extent and effects 
on health of intimate partner violence and non-partner 
violence in 24 000 women. The lifetime prevalence of 
physical or sexual intimate partner violence (or both) in 
women who had ever had a partner ranged from 15% 
to 71% (29-62% at most sites), though prevalence varied 
significantly between and within countries (large cities 
versus less populated areas).
We know more about the epidemiology of this type 
of violence than how to identify, prevent, and reduce it. 
However, recent research has made great strides, includ-
ing identifying optimal methods for further evaluation of 
case screening in emergency departments, family medi-
cine practices, and women’s health clinics; examining 
women’s acceptance of screening; identifying effective 
interventions; and identifying successful strategies for train-
ing and continuing medical education. Further research is 
still needed, though, especially to evaluate interventions 
and assess whether universal screening is effective.
We can learn much from WHO’s methodology and 
data collection methods, which relied, among other 
things, on partnerships with women’s organisations and 
with other key stakeholders within each country. Of the 
15 recommendations in the WHO report, two concern 
strengthening the health sector response (box 1) and 
take a clinical and public policy perspective, as others 
have done. The recommendations inform the basis for 
defining the competency of doctors when dealing with 
intimate partner violence. If the identified competencies 
reflect the needs of patients, and, as much as possible, 
broader needs of society, then we are a small step closer 
to implementing these two WHO recommendations.
The CanMEDS (Canadian medical education direc-
tives for specialists) framework on the competency of 
doctors, which was developed by the Royal College of 
Physicians and Surgeons of Canada, is currently used 
in several countries. It is intended for use by educators, 
teachers, trainees, practising doctors, researchers, and 
other health professionals (for example, for understand-
ing how doctors work on teams). Although CanMEDS 
may not be completely transferable across specialties 
and jurisdictions or valid for non-specialists, it is useful 
to consider what constitutes competency when dealing 
with intimate partner violence.
CanMEDS recognises seven (overlapping) roles for 
doctors—medical expert (central role), communicator, 
collaborator, health advocate, manager, scholar, and pro-
fessional (box 2). Each role has its own elements and key 
enabling competencies that have been described in detail 
elsewhere. Box 3 gives examples of how the CanMEDS 
roles can help direct doctors towards practising effec-
tively when dealing with intimate partner violence. 
While CanMEDS has been used here for illustrative 
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various reasons, including interpreting the results of 
nutritional surveys, estimating potential beneficiary fig-
ures, and calculating entry and exit criteria for feeding 
programmes. Increased prevalence of severe wasting 
varies in different settings when using either the new 
WHO standards or the NCHS-WHO references. This 
fact makes the interpretation of nutritional surveys dif-
ficult and means that results cannot be converted from 
one to the other by using a simple algorithm. During 
the transition period, therefore, both the WHO stand-
ards and the NCHS-WHO references should be used 
until the implications of these differences are better 
understood.
The choice of using the percentage of the median or 
the z score for admission of children to feeding centres 
is more complicated and should be related to functional 
outcomes. Weight for height expressed as a percentage 
of the median is used partly because it is a better predic-
tor of mortality than weight for height expressed as a z 
score when using the NCHS reference.5 We urgently 
need to study the functional significance of the weight 
for height indicators and investigate the suitable z score 
cut-offs for therapeutic and supplementary feeding in 
relation to mortality and other functional outcomes.
WHO, the United Nations World Food Programme, 
and Unicef are in the process of producing a joint state-
ment on community based management of severe acute 
malnutrition. New evidence using ready to use foods 
suggests that large numbers of children with severe 
acute malnutrition can be treated in their communities 
without being admitted to therapeutic feeding centres 
or health facilities.6 7
It is difficult and costly for community health work-
ers or volunteers to measure weight for height, and the 
mid-upper arm circumference is a good predictor of 
mortality. A mid-upper arm circumference less than 
110 mm has therefore been recommended as an indi-
cator of severe acute malnutrition in community based 
management of malnutrition. It would be useful to 
investigate whether this measurement can also be used 
as an indicator for admission to feeding programmes.
The international nutrition community working in 
emergencies has welcomed the introduction of the new 
WHO growth standard. Many will agree with Seal and 
Kerac, however, that a full assessment of the appro-
priate use of the new WHO standards in the diagno-
sis of acute malnutrition is urgently needed, and that 
this should be completed before they are adopted by 
agencies engaged in running nutritional programmes 
in emergencies.
BMJ | 7 april 2007 | VoluMe 334       707
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purposes, other competency frameworks could also be 
used. The concept of developing doctors’ competency 
in intimate partner violence is not new. To be valuable, 
these frameworks need to share the CanMEDS focus 
on what distinguishes doctors from other health profes-
sionals (medical expert) and on competencies that go 
beyond doctors’ technical knowledge and skills to the 
needs and expectations that society places upon them. 
An open debate about what constitutes such competen-
cies is needed to develop an international perspective 
and to guide training programmes and continuing medi-
cal education. We need to learn from educational lead-
ers about their experiences and evaluations of providing 
training about intimate partner violence using learning 
goals matched to competencies. We also need to find 
effective ways to deal with the resistance that may come 
from adding this to medical school curriculums.
We must recognise the difference between a doctor 
knowing and being able to perform a competency and 
actually implementing that competency in practice. 
Once we have international consensus on what consti-
tutes such competency, the next step is to assess it in 
practice, and ultimately to use it to set standards and 
measure performance.
Finally, we must recognise that efforts to identify what 
constitutes competency of doctors in dealing with inti-
mate partner violence must be considered in tandem 
with research, as evidence is still unavailable for many 
aspects of patient care (for example, universal screen-
ing versus diagnostic case-finding methods). All this can 
only be achieved if doctors and society acknowledge 
the epidemic of intimate partner violence, recognise it 
as a global health and human rights issue, and devote 
resources to dealing with it.
Box 1 | Recommendations from the WHO study1 aimed at strengthening the health sector response
Develop a comprehensive health sector response to the effects of violence against women
Identify roles for health professionals in advocating for prevention of violence and in providing 
services to women
Coordinate and work with other health professionals and with other sectors that care for abused 
women (for example, by creating formal referral processes and protocols)
Integrate appropriate non-stigmatising, non-blaming, respectful, secure, and confidential 
responses to violence against women into:
All aspects of care (such as emergency services, reproductive health services, mental 
health services, HIV related services)
Sensitising and training of health professionals
Use reproductive health services as entry points for identifying and supporting women in abusive 
relationships, and for delivering referral or support services
Sensitise and train reproductive health providers to recognise and respond appropriately to violence 
by having protocols to deal with it, using referral systems (if such systems are unavailable, providing 
information about legal and counselling options), ensuring confidentiality, and making women’s 
safety a priority
Add an anti-violence component to antenatal services, parenting classes, and other services that 
involve men
Box 2 |CanMEDS definitions of doctors’ roles. Reprinted with permission from appendix B of the 
CanMEDS 2005 physician competency framework9
Medical expert (the central role)
As Medical experts, physicians integrate all of the CanMEDS roles, applying medical knowledge, 
clinical skills, and professional attitudes in their provision of patient-centered care 
Communicator
As Communicators, physicians effectively facilitate the doctor-patient relationship and the dynamic 
exchanges that occur before, during, and after the medical encounter
Collaborator
As Collaborators, physicians effectively work within a healthcare team to achieve optimal patient care
Manager
As Managers, physicians are integral participants in healthcare organizations, organizing sustainable 
practices, making decisions about allocating resources, and contributing to the effectiveness of the 
healthcare system
Health advocate
As Health advocates, physicians responsibly use their expertise and influence to advance the health 
and well-being of individual patients, communities, and populations
Scholar
As Scholars, physicians demonstrate a lifelong commitment to reflective learning, as well as the 
creation, dissemination, application and translation of medical knowledge
Professional
As Professionals, physicians are committed to the health and well-being of individuals and society 
through ethical practice, profession-led regulation, and high personal standards of behaviour
Box 3 | Key features of the health sector WHO 
recommendations,1 with examples of CanMEDS roles9 in 
dealing with intimate partner violence 
Integrating appropriate responses to violence against women 
into all aspects of clinical care
Medical expert
Apply best practice to identify, intervene, and refer cases of 
intimate partner violence
Professional
Deliver ethical, humane and compassionate care, recognising 
that blame may be cast, which may cause secondary 
adverse effects. Recognise limitations in expertise (and seek 
consultation if necessary)
Communicator
Facilitate patient centred therapeutic communication, including 
active empathic listening to establish trust. Work therapeutically 
with victims of intimate partner violence and share decision 
making
Manager
Participate in health systems for collaborative decision making 
and quality improvement. Victims of intimate partner violence 
need health services; doctors must manage and improve the 
effectiveness of their individual provider and overall programme 
within healthcare systems
Scholar
Identify and apply evidence based intimate partner violence 
screening and interventions, identify knowledge or practice gaps 
and model these competencies for others
Advocating for prevention and for services
Health advocate and medical expert
Use medical expertise and influence to improve the overall 
health of patients and populations. Identify and apply health 
determinants (social, cultural, economic) and strategies to 
promote health and prevent disease. Doctors must know how 
to help victims of intimate partner violence in navigating local 
systems and obtaining appropriate resources
Working with other health professionals and other sectors
Collaborator
Work effectively and appropriately within health and non-health 
sectors to facilitate coordinated intimate partner violence 
responses for individual patients and populations
Sensitising and training health professionals
Scholar
Educate patients and other providers about intimate partner 
violence; engage in lifelong learning through critical appraisal of 
evidence and evidence based practice
Professional
Serve as a role model; commit to appropriately dealing with 
intimate partner violence
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Recent data published by the Health Protection 
Agency (HPA) show that each year in England 
around 7000 inpatients have methicillin resistant 
Staphylococcus aureus (MRSA) bacteraemia and more 
than 50 000 inpatients aged 65 years and over have 
Clostridium difficile infections.1 C difficile cases rose 
by 5.5% in 2006 compared with 2005, whereas 
MRSA cases fell by 4.3% over a similar period. 
HPA spokespeople said they thought that the rate 
of increase of C difficile was slowing and MRSA 
rates had reached a plateau.
My own time series analyses of the reported data 
failed to detect any significant change in rates of 
C difficile or MRSA, though C difficile increases 
significantly during winter (www.geriatric.med.
ed.ac.uk/john_starr.htm). The seasonal variation 
may be a result of many older people who require 
antibiotic treatment being admitted to hospital at 
that time of year. Despite the HPA data, there is 
a consensus that hospital acquired infection rates 
remain high and that recent control measures are 
having only a limited effect, especially on C dif-
ficile. With more than 2200 deaths attributed to C 
difficile on death certificates in England and Wales 
in 2004, the mortality rate is fast approaching that 
for road traffic accidents and is now around half 
that for suicide.2
Control of C difficile is difficult because, unlike 
MRSA, alcohol hand scrubs are ineffective and its 
spores are resistant to routine hospital cleaning.3 
Moreover, old and frail patients are at highest risk 
of infection with C difficile. Since older people 
are living longer, hospital admissions of people 
over 85 years have increased relative to other age 
groups.4 This continuing change in case mix is 
likely to increase the absolute number of reported 
cases.
In December 2006, the Department of Health 
issued a letter on healthcare associated infections, 
in particular infection caused by C difficile, which 
called for urgent action.5 In addition to hand 
hygiene and environmental cleaning, recommen-
dations include prudent antibiotic prescribing, 
isolation of infected patients, and use of personal 
protective equipment. Although there is a trend for 
reduced prescription of antibiotics in the comm- 
unity, it remains high in hospitals and accounts for 
59% of prescription costs.6 7 Theoretically, isola-
tion of infected patients should not be difficult. The 
National Health Service in England still has around 
150 000 beds and even if just 20% of these are 
single rooms that can be used for isolation purposes, 
there should still be more than adequate capacity. 
However, the clustering of cases can put a strain 
on local resources. This is a particular concern 
with the emergence of hypervirulent strains.8
Another factor that may be driving the inci-
dence of infection with C difficile is the community 
reservoir. Carriage rates in healthy people in the 
community may be around 5%, perhaps substan-
tially higher in those connected with hospitals, 
and this may lead to community acquired infec-
tion.9 Indeed, the relative increase in community 
acquired C difficile far outstrips that seen in hospital, 
despite reduced antibiotic use, and may relate to 
increased use of proton pump inhibitors and other 
drugs that suppress gastric acid production.10 More 
than 13 000 cases of community acquired C difficile 
occur each year in the UK, three quarters of which 
are in people who have not been in hospital dur-
ing the previous year. In contrast, the HPA iden-
tified fewer than 100 community acquired cases 
of MRSA between 2003 and 2005. This raises the 
question of whether C difficile can still be thought 
of as purely a hospital acquired infection and, if 
not, whether other infection control measures are 
needed, such as screening people in the community 
before they are admitted electively.
Early accurate diagnosis is fundamental to any 
infection control programme, whether based in 
hospital or the community. Laboratory methods 
to detect C difficile have varied considerably in 
the UK.11 Though variation has been reduced in 
England, it is still difficult to make comparisons 
with data from other countries, and thus assess the 
effects of their infection control policies. Denmark, 
for example, preferred culture to toxin detection as 
a diagnostic tool. Denmark also reported two fatal 
cases of C difficile enterocolitis in elephants in 2006, 
a reminder that animals, including household pets, 
can be a reservoir for the organism.
A report from the HPA published last year rec-
ommended greater international cooperation to 
tackle C difficile by sharing information about the 
appearance of new strains or changes in the preva-
lence of known strains.
It also emphasised that infection control guide-
lines have stayed essentially the same for more than 
a decade, and were implemented inconsistently 
across England.12 The recent HPA report presents 
a mixed message. Although both C difficile and 
MRSA are closely associated with use of antibiot-
ics, in other ways they are quite different. Infection 
control policies for MRSA have been more success-
ful than for C difficile, yet data on hospital acquired 
infections are often grouped together. In particular, 
because of the rise in community acquired infec-
tion it is important to consider whether a C difficile 
infection control policy solely focused on hospitals 
remains appropriate.
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